3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Infections
1
Hematologic Neoplasms
1
Agammaglobulinemia
1
Interventions
fludarabine phosphate
19
fludarabine
18
Cyclophosphamide
16
Tacrolimus
12
Whole-Body Irradiation
11
Melphalan
11
Mycophenolic Acid
10
Bortezomib
9
Busulfan
8
trametinib
7
Dexamethasone
7
thymoglobulin
6
Stem Cell Transplantation
6
Lenalidomide
6
Cyclosporine
6
Sirolimus
5
Nivolumab
5
Methotrexate
5
dabrafenib
4
Rituximab
4
Peripheral Blood Stem Cell Transplantation
4
Granulocyte Colony-Stimulating Factor
4
Antilymphocyte Serum
4
Alemtuzumab
4
daratumumab
3
aldesleukin
3
Thiotepa
3
Specimen Handling
3
Ipilimumab
3
Interleukin-2
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Clavulanic Acid
×
Plasma cell
×
Clear all
NCT05678621
2024-04-19
RATIONALISE
Monash University
Phase 2/3
Recruiting
300 enrolled